NO20050921L - Nye fysiologisk aktive substanser - Google Patents
Nye fysiologisk aktive substanserInfo
- Publication number
- NO20050921L NO20050921L NO20050921A NO20050921A NO20050921L NO 20050921 L NO20050921 L NO 20050921L NO 20050921 A NO20050921 A NO 20050921A NO 20050921 A NO20050921 A NO 20050921A NO 20050921 L NO20050921 L NO 20050921L
- Authority
- NO
- Norway
- Prior art keywords
- active substances
- physiologically active
- new physiologically
- inhibition
- same
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002224105 | 2002-07-31 | ||
| PCT/JP2003/009753 WO2004011661A1 (ja) | 2002-07-31 | 2003-07-31 | 新規生理活性物質 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050921L true NO20050921L (no) | 2005-04-28 |
Family
ID=31184996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050921A NO20050921L (no) | 2002-07-31 | 2005-02-21 | Nye fysiologisk aktive substanser |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7256178B2 (de) |
| EP (1) | EP1548121B1 (de) |
| JP (1) | JP4328293B2 (de) |
| KR (1) | KR101285695B1 (de) |
| CN (1) | CN1671856B (de) |
| AU (1) | AU2003252445B2 (de) |
| BR (1) | BR0313039A (de) |
| CA (1) | CA2494536C (de) |
| MX (1) | MXPA05001104A (de) |
| NO (1) | NO20050921L (de) |
| NZ (1) | NZ537830A (de) |
| RU (1) | RU2338741C2 (de) |
| WO (1) | WO2004011661A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) * | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| RU2330069C2 (ru) * | 2002-11-29 | 2008-07-27 | Мершан Корпорейшн | Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae |
| CN1886505A (zh) | 2003-11-27 | 2006-12-27 | 美露香株式会社 | 参与大环内酯类化合物的羟化作用的dna |
| ATE469985T1 (de) * | 2004-02-06 | 2010-06-15 | Eisai R&D Man Co Ltd | Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel |
| CN1977046A (zh) * | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| WO2007110705A2 (en) * | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide as inhibitors of mhc class ii |
| CN101282967B (zh) | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| WO2008016187A1 (en) | 2006-08-02 | 2008-02-07 | Eisai R & D Management Co., Ltd. | Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| US7790887B2 (en) * | 2007-01-29 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same |
| US20080312317A1 (en) * | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| GB0821539D0 (en) * | 2008-11-25 | 2008-12-31 | Merlion Pharmaceuticals Pte Ltd | Therapeutic compounds and their use |
| RS58400B1 (sr) | 2014-05-15 | 2019-04-30 | Eisai R&D Man Co Ltd | Jedinjenja pladienolid piridina i postupci primene |
| EP3344780B1 (de) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Spleissvarianten in zusammenhang mit neomorphen sf3b1-mutanten |
| IL259198B2 (en) | 2015-11-18 | 2023-04-01 | Eisai R&D Man Co Ltd | A solid form of paladinolide pyridine compound and methods of its use |
| JP2020514348A (ja) | 2017-03-15 | 2020-05-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライセオソーム変異及びその使用 |
| CN111727059A (zh) | 2017-10-31 | 2020-09-29 | 卫材研究发展管理有限公司 | 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法 |
| CA3096400A1 (en) | 2018-04-09 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Certain pladienolide compounds and methods of use |
| CA3096424A1 (en) | 2018-04-12 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| IL278740B2 (en) | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
| CN119405833A (zh) * | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| CN111973589A (zh) * | 2019-05-21 | 2020-11-24 | 中国科学院近代物理研究所 | pladienolide B在增强宫颈癌细胞辐射敏感性中的应用 |
| US20240043928A1 (en) | 2020-11-04 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04352783A (ja) | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | １２員環マクロライド系化合物 |
| EP0639644A1 (de) * | 1993-08-16 | 1995-02-22 | Ciba-Geigy Ag | Neue Makrolide und ihre Verwendung |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| EE200100422A (et) * | 1999-02-11 | 2002-12-16 | Schering Aktiengesellschaft | Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine |
| TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI233361B (en) * | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
-
2003
- 2003-07-31 RU RU2005105312/04A patent/RU2338741C2/ru not_active IP Right Cessation
- 2003-07-31 AU AU2003252445A patent/AU2003252445B2/en not_active Ceased
- 2003-07-31 US US10/522,731 patent/US7256178B2/en not_active Expired - Fee Related
- 2003-07-31 WO PCT/JP2003/009753 patent/WO2004011661A1/ja not_active Ceased
- 2003-07-31 EP EP20030771459 patent/EP1548121B1/de not_active Expired - Lifetime
- 2003-07-31 JP JP2004524326A patent/JP4328293B2/ja not_active Expired - Fee Related
- 2003-07-31 KR KR1020057001794A patent/KR101285695B1/ko not_active Expired - Fee Related
- 2003-07-31 NZ NZ537830A patent/NZ537830A/en not_active IP Right Cessation
- 2003-07-31 CA CA2494536A patent/CA2494536C/en not_active Expired - Fee Related
- 2003-07-31 MX MXPA05001104A patent/MXPA05001104A/es active IP Right Grant
- 2003-07-31 BR BR0313039-8A patent/BR0313039A/pt not_active IP Right Cessation
- 2003-07-31 CN CN038183129A patent/CN1671856B/zh not_active Expired - Fee Related
-
2005
- 2005-02-21 NO NO20050921A patent/NO20050921L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1671856A (zh) | 2005-09-21 |
| EP1548121A1 (de) | 2005-06-29 |
| WO2004011661A1 (ja) | 2004-02-05 |
| KR20050044898A (ko) | 2005-05-13 |
| NZ537830A (en) | 2007-12-21 |
| AU2003252445A1 (en) | 2004-02-16 |
| CN1671856B (zh) | 2010-05-12 |
| RU2005105312A (ru) | 2005-11-20 |
| MXPA05001104A (es) | 2005-09-08 |
| BR0313039A (pt) | 2005-08-09 |
| CA2494536A1 (en) | 2004-02-05 |
| JP4328293B2 (ja) | 2009-09-09 |
| AU2003252445B2 (en) | 2009-09-17 |
| US7256178B2 (en) | 2007-08-14 |
| JPWO2004011661A1 (ja) | 2005-11-24 |
| RU2338741C2 (ru) | 2008-11-20 |
| EP1548121A4 (de) | 2010-11-03 |
| KR101285695B1 (ko) | 2013-07-12 |
| EP1548121B1 (de) | 2015-04-29 |
| US20050245514A1 (en) | 2005-11-03 |
| CA2494536C (en) | 2011-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092033L (no) | Nye forbindelser | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
| NO20074657L (no) | Nitrogenholdige aromatiske ringforbindelser | |
| NO20061793L (no) | 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer | |
| WO2005046589A3 (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
| SE0302760D0 (sv) | New compounds | |
| NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
| NO20073663L (no) | Tiazol-4-karboksamid-derivater som mGluR5 antagonister | |
| NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
| MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
| MX2009004096A (es) | Metabolitos de talarozol. | |
| NO20050828L (no) | lndol-3-svovelderivater | |
| EA200701745A1 (ru) | Циклопропанкарбоксамидные производные | |
| EA200600621A1 (ru) | Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств | |
| NO20080394L (no) | N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav | |
| NO20055143L (no) | Doseringsformer innbefattende AG013736 | |
| NO20055632L (no) | Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater | |
| WO2006113552A8 (en) | Cyanoarylamines | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| NO20070089L (no) | DPP-IV inhibitorer | |
| NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
| NO20064576L (no) | Pyrimidin-derivater for behandling av avvikende celle vekst |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |